Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

rance, legal and professional fees

associated with being a public company.

Employee stock-based compensation expense recorded in the fourth

quarter of 2007 was $5.2 million. Of the total $5.2 million of

non-cash charges, $1.0 million was recorded in R&D expenses and

$4.2 million was recorded in G&A expenses. In the third quarter of

2007 and the fourth quarter of 2006, total stock-based compensation was

$5.2 million and $1.6 million, respectively. For the full year of

2007, total stock-based compensation was $19.5 million, up from

$6.1 million in the prior year. The increase in stock-based

compensation is primarily the result of the higher fair value of

options granted during 2007 compared to options granted in prior

periods.

-- Net loss for the fourth quarter of 2007 was $20.7 million. This

compares to a net loss of $21.9 million in the third quarter of 2007,

and $11.9 million in the fourth quarter of 2006. For the full year of

2007, net loss was $74.1 million, up from $63.5 million for the full

year of 2006.

-- Net loss per common share for the fourth quarter of 2007 was $0.78,

compared to $0.82 in the third quarter of 2007 and $0.54 in the fourth

quarter of 2006. For the full year of 2007, net loss per common share

was $2.81, compared to $3.97 in the full year of 2006.

-- Cash and marketable securities decreased by $16.2 million during the

fourth quarter. Changes included $20.7 million of net losses and

decreases in accrued R&D expenses and accounts payable of $2.5 million,

offset by $5.3 million in non-cash depreciation, amortization, and

stock-based compensation expenses, decreases in prepaid expenses of

$1.6 million and net decreases in other working capital of

$0.1 million.

-- Vanda's cash, cash equivalents, an
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Los Angeles, CA (PRWEB) July 10, 2014 ... Analytical and Bioanalytical techniques during 18-20 August, 2014 at ... to critically review the recent developments in Analytical & ... across the globe. , Speaking on this occasion, Dr. ... that Analytica Acta conference is a remarkable one ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... our laptops and electric vehicles could store more energy ... help of a sponge-like silicon material. , Researchers ... used in one of the battery,s electrodes, as silicon ... of graphite. A paper describing the material,s performance as ... Nature Communications . , "Silicon has long been sought ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2Silicon sponge improves lithium-ion battery performance 2Silicon sponge improves lithium-ion battery performance 3
... Rising star Divine Skin Inc. (DSKX), which has been expanding ... long-time leader in the cosmetics industry, to become its president. ... Divine Skin because I believe their innovative products are unmatched ... with a ,wow, factor." A dozen Divine ...
... 25, 2011 For the first time, Eli Lilly and ... to more than 800 grassroots projects across the globe and ... Foundation—doubling the value and impact of each employee,s charitable contribution. ... to offer its employees across the world a customized Lilly ...
... Sciences International, Inc. (Nasdaq: BDSI ) announced ... portion of its Phase 3 clinical trial assessing the ... of moderate to severe chronic pain, signifying completion of ... are very pleased to have brought to completion our ...
Cached Biology Technology:Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX) 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 2Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 3Lilly Global Giving Puts Power of Philanthropy in Employees' Hands 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... . X-ray ... of X-rays through a specimen instead of attenuation resulting ... often of much higher quality than those based on ... Pfeiffer are particularly interested in developing new approaches for ... imaging. One main goal is to make this method ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... a part of the National Institutes of Health ... million to fund three new Institutional Development Awards ... concentrating on one general area of research ... research infrastructure. The IDeA program is designed to ...
... altering the Earths chemistry. Many of societys most pressing ... from human activities that disrupt natural chemical cycles. Moving ... reversing actions that have such a huge impact on ... of the Institute of Ecosystem Studies, Dr. William H. ...
... -- Three researchers at the Albert Einstein College of ... Research Foundation (BCRF). Drs. Thomas Rohan, Susan Horwitz and ... its ongoing effort to support the advancement of breast ... is its mission, which is to achieve prevention and ...
Cached Biology News:NIH grants $33 M in institutional development awards to 3 states 2Biogeochemistry -- A window into the Earth's ecological health 2Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Biology Products: